{
    "clinical_study": {
        "@rank": "87166", 
        "acronym": "ITP", 
        "brief_summary": {
            "textblock": "The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune\n      Thrombocytopenic Purpura (RITP) and explore the further mechanism."
        }, 
        "brief_title": "Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Immune Thrombocytopenic Purpura", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Thrombocytopenia", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and\n      autoimmune diseases. Many studies have shown that the drug contributes to the expansion of\n      regulatory T cells and preserves the highly suppressive function of autoreactive T cells.\n      Patients with RITP often display a decreased  proportion of regulatory T cells by flow\n      cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP\n      patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnoses of idiopathic thrombocytopenic purpura\n\n          -  Hormone and immune suppression, splenectomy is invalid\n\n        Exclusion Criteria:\n\n          -  patients had a bad tolerance to rapamycin\n\n          -  platelet counts < 10*10E9/L during the treatment of rapamycin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "35 patients using rapamycin therapy were observed before and after treatment,who did not\n        response to any other administrations including prednisone and immunosuppressive drugs,\n        even splenectomy ."
            }
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672151", 
            "org_study_id": "jsxys456"
        }, 
        "intervention": {
            "description": "4mg oral administration on the first day, 2 mg/d oral administration for 3 months", 
            "intervention_name": "rapamycin", 
            "intervention_type": "Drug", 
            "other_name": "sirolimus"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Refractory Immune Thrombocytopenic Purpura", 
            "rapamycin", 
            "regulatory T cells"
        ], 
        "lastchanged_date": "August 23, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Suzhou", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "215006"
                }, 
                "name": "Jiangsu Institute of Hematology"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia", 
        "overall_official": {
            "last_name": "zhaoyue wang, doctor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: National Natural Science Foundation", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672151"
        }, 
        "responsible_party": {
            "investigator_affiliation": "First Affiliated Hospital of Suzhou Medical College", 
            "investigator_full_name": "Zhaoyue Wang", 
            "investigator_title": "Jiangsu Institute of hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "First Affiliated Hospital of Suzhou Medical College", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "First Affiliated Hospital of Suzhou Medical College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}